Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC Meeting Abstract
| Authors: | Chaft, J. E.; Costa, D. B.; Muzikansky, A.; Shrager, J. B.; Lanuti, M.; Huang, J.; Ramchandran, K.; Rangachari, D.; Huberman, M.; Piotrowska, Z.; Kris, M. G.; Azzoli, C. G.; Sequist, L. V.; Neal, J. W. |
| Abstract Title: | Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC |
| Meeting Title: | 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2019 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-05-20 |
| Start Page: | 458s |
| Language: | English |
| ACCESSION: | WOS:000487345806385 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2019.37.15_suppl.8507 |
| Notes: | Meeting Abstract : 8507 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
